Erasca Narrows Loss 46% in Fiscal Q2

Erasca (NASDAQ:ERAS), a clinical-stage biotechnology company focused on developing cancer therapies targeting the RAS/MAPK pathway, released its second quarter results on August 12, 2025. The company highlighted accelerated progress for two key clinical programs and reported operating expenses well below last year, significantly narrowing its net loss. Earnings per share (GAAP) was a loss of $0.12, missing consensus estimates by a small margin. Revenue remained at zero as expected for a company without commercialized products. The quarter showed continued cost controls and clinical momentum, though future milestones remain tied to upcoming clinical trial results expected in 2026. Source: Analyst estimates for the quarter provided by FactSet. Erasca seeks to discover and develop therapies that target the RAS/MAPK signaling pathway, a critical driver of many cancers. This pathway is involved in controlling cell growth, and its mutations are found in a large number of solid tumors.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool